In the SCC patient cohort with PD-L1 immunopositive tumors, the risk of tumor related death was significantly increased (p = 0.01) (Figure 4a) which was also the case for the risk of recurrence (p = 0.05) (Figure 4b). This evidence concerns the gene CD274 and neoplasm.